Multiomic Health, a UK-based biotech startup founded by Robert Thong, has raised $6.2M in seed funding from Hoxton Ventures, MMC Ventures, Verve Ventures, and Ada Ventures to revolutionize the way we understand and treat metabolic syndrome, the world's largest healthcare burden. With over 3.5 billion adults affected by this cluster of closely-related diseases, including atherosclerotic cardiovascular disease, type 2 diabetes, chronic kidney disease, and non-alcoholic fatty liver, Multiomic Health is addressing a major unmet need by developing high-fidelity tools to focus the right treatments on the right patients. While the market for metabolic syndrome is 1.6 times larger than oncology, it attracts only 40% of the VC dollars, highlighting the lack of investment in this area. 

Multiomic Health's unique combination of data science and biology expertise enables the data-driven development of therapeutics, using computational systems biology to unlock an understanding of complex biological systems. The startup's ML-enabled data science and rapidly falling omics costs have changed the game and they are aiming to become the leader in this space. Multiomic Health's approach includes multi-omic analysis, including genomics, epigenomics, transcriptomics, proteomics, metabolomics, and gut microbiome analysis, to better understand how someone's genes predispose to disease and influence drug response.